Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.

Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $181.11, a high estimate of ...

GW Pharmaceuticals’ cannabis-derived drug Epidyolex has been approved in Europe for two kinds of rare childhood epilepsy. The European Commission approved the drug, an oral solution containing ...

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion takeover by Jazz Pharma.

GW Pharmaceuticals is a cutting-edge UK-based biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and the development of ...

For instance, GW Pharma stated in February 2024 that ... for the highest revenue-grossing segment in the global cannabis pharmaceuticals market in 2023 and is predicted to grow at the fastest ...

The success of Epidiolex prompted several companies to attempt to create generic versions. Jazz Pharmaceuticals plc (NASDAQ: ...

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range ...